ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas

International Journal of Molecular Sciences

Volumn 14, Issue 9, 2013, Pages 18824-18849

  Samartzis, Eleftherios P ^a   Noske, Aurelia ^a   Dedes, Konstantin J ^a   Fink, Daniel ^a   Imesch, Patrick ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

ARID1A; Endometrioid ovarian carcinoma (EnOC); Endometriosis; Ovarian clear cell carcinoma (OCCC); PI3K AKT pathway; PIK3CA

Indexed keywords

AT RICH INTERACTING DOMAIN CONTAINING PROTEIN 1A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARID1A GENE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLEAR CELL CARCINOMA; DISEASE ASSOCIATION; ENDOMETRIOID OVARIAN CARCINOMA; ENDOMETRIOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SUBUNIT; GENE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCATION; GENE LOSS; GENE MUTATION; HUMAN; MUTATIONAL ANALYSIS; OVARIAN CLEAR CELL CARCINOMA; OVARY CANCER; PROTEIN PROTEIN INTERACTION; REVIEW;

ENDOMETRIOSIS; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84884172829     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140918824     Document Type: Review

References (163)

1. Cornen, S.; Adelaide, J.; Bertucci, F.; Finetti, P.; Guille, A.; Birnbaum, D.J.; Birnbaum, D.; Chaffanet, M. Mutations and deletions of arid1a in breast tumors. Oncogene 2012, 31, 4255-4256.
2. Popovic, R.; Licht, J.D. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2012, 2, 405-413.
3. Oike, T.; Ogiwara, H.; Tominaga, Y.; Ito, K.; Ando, O.; Tsuta, K.; Mizukami, T.; Shimada, Y.; Isomura, H.; Komachi, M., et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor brg1. Cancer Res. 2013, doi:10.1158/0008-5472.CAN-12-4593.
4. Wiegand, K.C.; Shah, S.P.; Al-Agha, O.M.; Zhao, Y.; Tse, K.; Zeng, T.; Senz, J.; McConechy, M.K.; Anglesio, M.S.; Kalloger, S.E., et al. Arid1a mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 2010, 363, 1532-1543.
5. Jones, S.; Wang, T.L.; Shih, I.M.; Mao, T.L.; Nakayama, K.; Roden, R.; Glas, R.; Slamon, D.; Diaz, L.A.; Vogelstein, B., et al. Frequent mutations of chromatin remodeling gene arid1a in ovarian clear cell carcinoma. Science 2010, 330, 228-231.
6. Birrer, M.J. The origin of ovarian cancer-Is it getting clearer? N. Engl. J. Med. 2010, 363, 1574-1575.
7. Nissenblatt, M. Endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 2011, 364, 482-483.
8. Bulun, S.E. Endometriosis. N. Engl. J. Med. 2009, 360, 268-279.
9. Buck Louis, G.M.; Hediger, M.L.; Peterson, C.M.; Croughan, M.; Sundaram, R.; Stanford, J.; Chen, Z.; Fujimoto, V.Y.; Varner, M.W.; Trumble, A., et al. Incidence of endometriosis by study population and diagnostic method: The endo study. Fertil. Steril. 2011, 96, 360-365.
10. Giudice, L.C.; Kao, L.C. Endometriosis. Lancet 2004, 364, 1789-1799.
11. Giudice, L.C. Clinical practice. Endometriosis. N. Engl. J. Med. 2010, 362, 2389-2398.
12. Somigliana, E.; Vigano', P.; Parazzini, F.; Stoppelli, S.; Giambattista, E.; Vercellini, P. Association between endometriosis and cancer: A comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol. Oncol. 2006, 101, 331-341.
13. Sampson, J.A. Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch. Surg. 1925, 10, 1-72.
14. Ness, R.B. Endometriosis and ovarian cancer: Thoughts on shared pathophysiology. Am. J. Obstet. Gynecol. 2003, 189, 280-294.
15. Brinton, L.A.; Gridley, G.; Persson, I.; Baron, J.; Bergqvist, A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am. J. Obstet. Gynecol. 1997, 176, 572-579.
16. Melin, A.; Sparen, P.; Persson, I.; Bergqvist, A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum. Reprod. 2006, 21, 1237-1242.
17. Kobayashi, H.; Sumimoto, K.; Moniwa, N.; Imai, M.; Takakura, K.; Kuromaki, T.; Morioka, E.; Arisawa, K.; Terao, T. Risk of developing ovarian cancer among women with ovarian endometrioma: A cohort study in shizuoka, Japan. Int. J. Gynecol. Cancer 2007, 17, 37-43.
18. Rossing, M.A.; Cushing-Haugen, K.L.; Wicklund, K.G.; Doherty, J.A.; Weiss, N.S. Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control 2008, 19, 1357-1364.
19. Wu, A.H.; Pearce, C.L.; Tseng, C.C.; Templeman, C.; Pike, M.C. Markers of inflammation and risk of ovarian cancer in los angeles county. Int. J. Cancer 2009, 124, 1409-1415.
20. Ness, R.B.; Cramer, D.W.; Goodman, M.T.; Kjaer, S.K.; Mallin, K.; Mosgaard, B.J.; Purdie, D.M.; Risch, H.A.; Vergona, R.; Wu, A.H. Infertility, fertility drugs, and ovarian cancer: A pooled analysis of case-control studies. Am. J. Epidemiol. 2002, 155, 217-224.
21. Merritt, M.A.; Green, A.C.; Nagle, C.M.; Webb, P.M.; Cancer, A.C.S.O.; Group, A.O.C.S. Talcum powder, chronic pelvic inflammation and nsaids in relation to risk of epithelial ovarian cancer. Int. J. Cancer 2008, 122, 170-176.
22. Venn, A.; Watson, L.; Bruinsma, F.; Giles, G.; Healy, D. Risk of cancer after use of fertility drugs with in vitro fertilisation. Lancet 1999, 354, 1586-1590.
23. Borgfeldt, C.; Andolf, E. Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet. Gynecol. Scand. 2004, 83, 395-400.
24. Brinton, L.A.; Sakoda, L.C.; Sherman, M.E.; Frederiksen, K.; Kjaer, S.K.; Graubard, B.I.; Olsen, J.H.; Mellemkjaer, L. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol. Biomark. Prev. 2005, 14, 2929-2935.
25. Ness, R.B.; Grisso, J.A.; Cottreau, C.; Klapper, J.; Vergona, R.; Wheeler, J.E.; Morgan, M.; Schlesselman, J.J. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000, 11, 111-117.
26. Brinton, L.A.; Lamb, E.J.; Moghissi, K.S.; Scoccia, B.; Althuis, M.D.; Mabie, J.E.; Westhoff, C.L. Ovarian cancer risk associated with varying causes of infertility. Fertil. Steril. 2004, 82, 405-414.
27. Vercellini, P.; Parazzini, F.; Bolis, G.; Carinelli, S.; Dindelli, M.; Vendola, N.; Luchini, L.; Crosignani, P.G. Endometriosis and ovarian cancer. Am. J. Obstet. Gynecol. 1993, 169, 181-182.
28. Pearce, C.L.; Templeman, C.; Rossing, M.A.; Lee, A.; Near, A.M.; Webb, P.M.; Nagle, C.M.; Doherty, J.A.; Cushing-Haugen, K.L.; Wicklund, K.G., et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies. Lancet Oncol. 2012, 13, 385-394.
29. Sieh, W.; Kobel, M.; Longacre, T.A.; Bowtell, D.D.; Defazio, A.; Goodman, M.T.; Hogdall, E.; Deen, S.; Wentzensen, N.; Moysich, K.B., et al. Hormone-receptor expression and ovarian cancer survival: An ovarian tumor tissue analysis consortium study. Lancet Oncol. 2013, 14, 853-862.
30. Kurman, R.J.; Shih, I.M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum. Pathol. 2011, 42, 918-931.
31. Kurman, R.J.; Shih, I.M. Pathogenesis of ovarian cancer: Lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 2008, 27, 151-160.
32. Shih, I.M.; Kurman, R.J. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 2004, 164, 1511-1518.
33. Shih, I.M.; Kurman, R.J. Molecular pathogenesis of ovarian borderline tumors: New insights and old challenges. Clin. Cancer Res. 2005, 11, 7273-7279.
34. Kurman, R.J.; Visvanathan, K.; Roden, R.; Wu, T.C.; Shih, I.M. Early detection and treatment of ovarian cancer: Shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am. J. Obstet. Gynecol. 2008, 198, 351-356.
35. Vang, R.; Shih, I.M.; Kurman, R.J. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 2013, 62, 44-58.
36. Dubeau, L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008, 9, 1191-1197.
37. Hough, C.D.; Sherman-Baust, C.A.; Pizer, E.S.; Montz, F.J.; Im, D.D.; Rosenshein, N.B.; Cho, K.R.; Riggins, G.J.; Morin, P.J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000, 60, 6281-6287.
38. Dubeau, L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: Does the emperor have no clothes? Gynecol. Oncol. 1999, 72, 437-442.
39. Crum, C.P.; Drapkin, R.; Miron, A.; Ince, T.A.; Muto, M.; Kindelberger, D.W.; Lee, Y. The distal fallopian tube: A new model for pelvic serous carcinogenesis. Curr. Opin. Obstet. Gynecol. 2007, 19, 3-9.
40. Roh, M.H.; Kindelberger, D.; Crum, C.P. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: Clues to serous tumor origin? Am. J. Surg. Pathol. 2009, 33, 376-383.
41. Semmel, D.R.; Folkins, A.K.; Hirsch, M.S.; Nucci, M.R.; Crum, C.P. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod. Pathol. 2009, 22, 985-988.
42. Wei, J.J.; Wu, J.; Luan, C.; Yeldandi, A.; Lee, P.; Keh, P.; Liu, J. Hmga2: A potential biomarker complement to p53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am. J. Surg. Pathol. 2010, 34, 18-26.
43. Sehdev, A.S.; Kurman, R.J.; Kuhn, E.; Shih, I.M. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including rsf-1 (hbxap), cyclin e and fatty acid synthase. Mod. Pathol. 2010, 23, 844-855.
44. Kuhn, E.; Kurman, R.J.; Vang, R.; Sehdev, A.S.; Han, G.; Soslow, R.; Wang, T.L.; Shih, I.M. Tp53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J. Pathol. 2012, 226, 421-426.
45. Kuhn, E.; Meeker, A.; Wang, T.L.; Sehdev, A.S.; Kurman, R.J.; Shih, I.M. Shortened telomeres in serous tubal intraepithelial carcinoma: An early event in ovarian high-grade serous carcinogenesis. Am. J. Surg. Pathol. 2010, 34, 829-836.
46. Cibula, D.; Widschwendter, M.; Majek, O.; Dusek, L. Tubal ligation and the risk of ovarian cancer: Review and meta-analysis. Hum. Reprod. Update 2011, 17, 55-67.
47. Narod, S.A.; Sun, P.; Ghadirian, P.; Lynch, H.; Isaacs, C.; Garber, J.; Weber, B.; Karlan, B.; Fishman, D.; Rosen, B., et al. Tubal ligation and risk of ovarian cancer in carriers of brca1 or brca2 mutations: A case-control study. Lancet 2001, 357, 1467-1470.
48. Miracle-McMahill, H.L.; Calle, E.E.; Kosinski, A.S.; Rodriguez, C.; Wingo, P.A.; Thun, M.J.; Heath, C.W. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am. J. Epidemiol. 1997, 145, 349-357.
49. Hankinson, S.E.; Hunter, D.J.; Colditz, G.A.; Willett, W.C.; Stampfer, M.J.; Rosner, B.; Hennekens, C.H.; Speizer, F.E. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993, 270, 2813-2818.
50. Ogawa, S.; Kaku, T.; Amada, S.; Kobayashi, H.; Hirakawa, T.; Ariyoshi, K.; Kamura, T.; Nakano, H. Ovarian endometriosis associated with ovarian carcinoma: A clinicopathological and immunohistochemical study. Gynecol. Oncol. 2000, 77, 298-304.
51. Lim, M.C.; Chun, K.C.; Shin, S.J.; Lee, I.H.; Lim, K.T.; Cho, C.H.; Park, S.Y.; Nam, J.H. Clinical presentation of endometrioid epithelial ovarian cancer with concurrent endometriosis: A multicenter retrospective study. Cancer Epidemiol. Biomark. Prev. 2010, 19, 398-404.
52. Aris, A. Endometriosis-associated ovarian cancer: A ten-year cohort study of women living in the estrie region of quebec, canada. J. Ovarian Res. 2010, 3, 2.
53. Czernobilsky, B.; Morris, W.J. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet. Gynecol. 1979, 53, 318-323.
54. LaGrenade, A.; Silverberg, S.G. Ovarian tumors associated with atypical endometriosis. Hum. Pathol. 1988, 19, 1080-1084.
55. Anglesio, M.S.; Carey, M.S.; Kobel, M.; Mackay, H.; Huntsman, D.G.; Speakers, V.O.C.C.S. Clear cell carcinoma of the ovary: A report from the first ovarian clear cell symposium, June 24th, 2010. Gynecol. Oncol. 2011, 121, 407-415.
56. Sugiyama, T.; Kamura, T.; Kigawa, J.; Terakawa, N.; Kikuchi, Y.; Kita, T.; Suzuki, M.; Sato, I.; Taguchi, K. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000, 88, 2584-2589.
57. Itamochi, H.; Kigawa, J.; Terakawa, N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008, 99, 653-658.
58. Mackay, H.J.; Brady, M.F.; Oza, A.M.; Reuss, A.; Pujade-Lauraine, E.; Swart, A.M.; Siddiqui, N.; Colombo, N.; Bookman, M.A.; Pfisterer, J., et al. Prognostic relevance of uncommon ovarian histology in women with stage iii/iv epithelial ovarian cancer. Int. J. Gynecol. Cancer 2010, 20, 945-952.
59. Kobel, M.; Kalloger, S.E.; Huntsman, D.G.; Santos, J.L.; Swenerton, K.D.; Seidman, J.D.; Gilks, C.B.; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency; Vancouver, B.C. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int. J. Gynecol. Pathol. 2010, 29, 203-211.
60. McCluggage, W.G. My approach to and thoughts on the typing of ovarian carcinomas. J. Clin. Pathol. 2008, 61, 152-163.
61. Chan, J.K.; Teoh, D.; Hu, J.M.; Shin, J.Y.; Osann, K.; Kapp, D.S. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol. Oncol. 2008, 109, 370-376.
62. Jacoby, V.L.; Fujimoto, V.Y.; Giudice, L.C.; Kuppermann, M.; Washington, A.E. Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am. J. Obstet. Gynecol. 2010, 202, 514-521.
63. Takano, M.; Kikuchi, Y.; Yaegashi, N.; Kuzuya, K.; Ueki, M.; Tsuda, H.; Suzuki, M.; Kigawa, J.; Takeuchi, S.; Moriya, T., et al. Clear cell carcinoma of the ovary: A retrospective multicentre experience of 254 patients with complete surgical staging. Br. J. Cancer 2006, 94, 1369-1374.
64. Ho, C.M.; Huang, Y.J.; Chen, T.C.; Huang, S.H.; Liu, F.S.; Chang Chien, C.C.; Yu, M.H.; Mao, T.L.; Wang, T.Y.; Hsieh, C.Y. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol. Oncol. 2004, 94, 197-203.
65. Pectasides, D.; Fountzilas, G.; Aravantinos, G.; Kalofonos, C.; Efstathiou, H.; Farmakis, D.; Skarlos, D.; Pavlidis, N.; Economopoulos, T.; Dimopoulos, M.A. Advanced stage clear-cell epithelial ovarian cancer: The hellenic cooperative oncology group experience. Gynecol. Oncol. 2006, 102, 285-291.
66. Utsunomiya, H.; Akahira, J.; Tanno, S.; Moriya, T.; Toyoshima, M.; Niikura, H.; Ito, K.; Morimura, Y.; Watanabe, Y.; Yaegashi, N. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: A multicenter trial. Int. J. Gynecol. Cancer 2006, 16, 52-56.
67. Tan, D.S.; Kaye, S. Ovarian clear cell adenocarcinoma: A continuing enigma. J. Clin. Pathol. 2007, 60, 355-360.
68. Duska, L.R.; Garrett, L.; Henretta, M.; Ferriss, J.S.; Lee, L.; Horowitz, N. When 'never-events' occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol. Oncol. 2010, 116, 374-377.
69. Collaborative Group on Epidemiological Studies of Ovarian Cancer; Beral, V.; Gaitskell, K.; Hermon, C.; Moser, K.; Reeves, G.; Peto, R. Ovarian cancer and smoking: Individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012, 13, 946-956.
70. Maeda, D.; Shih, I.M. Pathogenesis and the role of arid1a mutation in endometriosis-related ovarian neoplasms. Adv. Anat. Pathol. 2013, 20, 45-52.
71. Eifel, P.; Hendrickson, M.; Ross, J.; Ballon, S.; Martinez, A.; Kempson, R. Simultaneous presentation of carcinoma involving the ovary and the uterine corpus. Cancer 1982, 50, 163-170.
72. Zaino, R.J.; Unger, E.R.; Whitney, C. Synchronous carcinomas of the uterine corpus and ovary. Gynecol. Oncol. 1984, 19, 329-335.
73. Ulbright, T.M.; Roth, L.M. Metastatic and independent cancers of the endometrium and ovary: A clinicopathologic study of 34 cases. Hum. Pathol. 1985, 16, 28-34.
74. Kline, R.C.; Wharton, J.T.; Atkinson, E.N.; Burke, T.W.; Gershenson, D.M.; Edwards, C.L. Endometrioid carcinoma of the ovary: Retrospective review of 145 cases. Gynecol. Oncol. 1990, 39, 337-346.
75. Falkenberry, S.S.; Steinhoff, M.M.; Gordinier, M.; Rappoport, S.; Gajewski, W.; Granai, C.O. Synchronous endometrioid tumors of the ovary and endometrium. A clinicopathologic study of 22 cases. J. Reprod. Med. 1996, 41, 713-718.
76. McMeekin, D.S.; Burger, R.A.; Manetta, A.; DiSaia, P.; Berman, M.L. Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol. Oncol. 1995, 59, 81-86.
77. Rutgers, J.L.; Scully, R.E. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis. Cancer 1988, 61, 340-348.
78. Kim, K.R.; Choi, J.; Hwang, J.E.; Baik, Y.A.; Shim, J.Y.; Kim, Y.M.; Robboy, S.J. Endocervical-like (mullerian) mucinous borderline tumours of the ovary are frequently associated with the kras mutation. Histopathology 2010, 57, 587-596.
79. Fukunaga, M.; Ushigome, S. Epithelial metaplastic changes in ovarian endometriosis. Mod. Pathol. 1998, 11, 784-788.
80. Wu, J.N.; Roberts, C.W. Arid1a mutations in cancer: Another epigenetic tumor suppressor? Cancer Discov. 2013, 3, 35-43.
81. Wilsker, D.; Probst, L.; Wain, H.M.; Maltais, L.; Tucker, P.W.; Moran, E. Nomenclature of the arid family of dna-binding proteins. Genomics 2005, 86, 242-251.
82. Wang, X.; Nagl, N.G.; Wilsker, D.; van Scoy, M.; Pacchione, S.; Yaciuk, P.; Dallas, P.B.; Moran, E. Two related arid family proteins are alternative subunits of human swi/snf complexes. Biochem. J. 2004, 383, 319-325.
83. Wilson, B.G.; Roberts, C.W. Swi/snf nucleosome remodellers and cancer. Nat. Rev. Cancer 2011, 11, 481-492.
84. Kozmik, Z.; Machon, O.; Kralova, J.; Kreslova, J.; Paces, J.; Vlcek, C. Characterization of mammalian orthologues of the drosophila osa gene: Cdna cloning, expression, chromosomal localization, and direct physical interaction with brahma chromatin-remodeling complex. Genomics 2001, 73, 140-148.
85. Flores-Alcantar, A.; Gonzalez-Sandoval, A.; Escalante-Alcalde, D.; Lomeli, H. Dynamics of expression of arid1a and arid1b subunits in mouse embryos and in cells during the cell cycle. Cell Tissue Res. 2011, 345, 137-148.
86. Beausoleil, S.A.; Jedrychowski, M.; Schwartz, D.; Elias, J.E.; Villen, J.; Li, J.; Cohn, M.A.; Cantley, L.C.; Gygi, S.P. Large-scale characterization of hela cell nuclear phosphoproteins. Proc. Natl. Acad. Sci. USA 2004, 101, 12130-12135.
87. Guan, B.; Wang, T.L.; Shih, I.M. Arid1a, a factor that promotes formation of swi/snf-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011, 71, 6718-6727.
88. Nie, Z.; Xue, Y.; Yang, D.; Zhou, S.; Deroo, B.J.; Archer, T.K.; Wang, W. A specificity and targeting subunit of a human swi/snf family-related chromatin-remodeling complex. Mol. Cell. Biol. 2000, 20, 8879-8888.
89. Shain, A.H.; Pollack, J.R. The spectrum of swi/snf mutations, ubiquitous in human cancers. PLoS One 2013, 8, e55119.
90. Wiegand, K.C.; Lee, A.F.; Al-Agha, O.M.; Chow, C.; Kalloger, S.E.; Scott, D.W.; Steidl, C.; Wiseman, S.M.; Gascoyne, R.D.; Gilks, B., et al. Loss of baf250a (arid1a) is frequent in high-grade endometrial carcinomas. J. Pathol. 2011, 224, 328-333.
91. Guan, B.; Mao, T.L.; Panuganti, P.K.; Kuhn, E.; Kurman, R.J.; Maeda, D.; Chen, E.; Jeng, Y.M.; Wang, T.L.; Shih, I.M. Mutation and loss of expression of arid1a in uterine low-grade endometrioid carcinoma. Am. J. Surg. Pathol. 2011, 35, 625-632.
92. Shain, A.H.; Giacomini, C.P.; Matsukuma, K.; Karikari, C.A.; Bashyam, M.D.; Hidalgo, M.; Maitra, A.; Pollack, J.R. Convergent structural alterations define switch/sucrose nonfermentable (swi/snf) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2012, 109, E252-E259.
93. Birnbaum, D.J.; Adelaide, J.; Mamessier, E.; Finetti, P.; Lagarde, A.; Monges, G.; Viret, F.; Goncalves, A.; Turrini, O.; Delpero, J.R., et al. Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer 2011, 50, 456-465.
94. Wang, K.; Kan, J.; Yuen, S.T.; Shi, S.T.; Chu, K.M.; Law, S.; Chan, T.L.; Kan, Z.; Chan, A.S.; Tsui, W.Y., et al. Exome sequencing identifies frequent mutation of arid1a in molecular subtypes of gastric cancer. Nat. Genet. 2011, 43, 1219-1223.
95. Zang, Z.J.; Cutcutache, I.; Poon, S.L.; Zhang, S.L.; McPherson, J.R.; Tao, J.; Rajasegaran, V.; Heng, H.L.; Deng, N.; Gan, A., et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 2012, 44, 570-574.
96. Abe, H.; Maeda, D.; Hino, R.; Otake, Y.; Isogai, M.; Ushiku, A.S.; Matsusaka, K.; Kunita, A.; Ushiku, T.; Uozaki, H., et al. Arid1a expression loss in gastric cancer: Pathway-dependent roles with and without epstein-barr virus infection and microsatellite instability. Virchows Arch. 2012, 461, 367-377.
97. Guichard, C.; Amaddeo, G.; Imbeaud, S.; Ladeiro, Y.; Pelletier, L.; Maad, I.B.; Calderaro, J.; Bioulac-Sage, P.; Letexier, M.; Degos, F., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 2012, 44, 694-698.
98. Fujimoto, A.; Totoki, Y.; Abe, T.; Boroevich, K.A.; Hosoda, F.; Nguyen, H.H.; Aoki, M.; Hosono, N.; Kubo, M.; Miya, F., et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 2012, 44, 760-764.
99. Huang, J.; Deng, Q.; Wang, Q.; Li, K.Y.; Dai, J.H.; Li, N.; Zhu, Z.D.; Zhou, B.; Liu, X.Y.; Liu, R.F., et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat. Genet. 2012, 44, 1117-1121.
100. Mamo, A.; Cavallone, L.; Tuzmen, S.; Chabot, C.; Ferrario, C.; Hassan, S.; Edgren, H.; Kallioniemi, O.; Aleynikova, O.; Przybytkowski, E., et al. An integrated genomic approach identifies arid1a as a candidate tumor-suppressor gene in breast cancer. Oncogene 2012, 31, 2090-2100.
101. Jones, S.; Li, M.; Parsons, D.W.; Zhang, X.; Wesseling, J.; Kristel, P.; Schmidt, M.K.; Markowitz, S.; Yan, H.; Bigner, D., et al. Somatic mutations in the chromatin remodeling gene arid1a occur in several tumor types. Hum. Mutat. 2012, 33, 100-103.
102. Maeda, D.; Mao, T.L.; Fukayama, M.; Nakagawa, S.; Yano, T.; Taketani, Y.; Shih, I.M. Clinicopathological significance of loss of arid1a immunoreactivity in ovarian clear cell carcinoma. Int. J. Mol. Sci. 2010, 11, 5120-5128.
103. Katagiri, A.; Nakayama, K.; Rahman, M.T.; Rahman, M.; Katagiri, H.; Nakayama, N.; Ishikawa, M.; Ishibashi, T.; Iida, K.; Kobayashi, H., et al. Loss of arid1a expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod. Pathol. 2012, 25, 282-288.
104. Yamamoto, S.; Tsuda, H.; Takano, M.; Tamai, S.; Matsubara, O. Loss of arid1a protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with pik3ca mutations. Mod. Pathol. 2012, 25, 615-624.
105. Lowery, W.J.; Schildkraut, J.M.; Akushevich, L.; Bentley, R.; Marks, J.R.; Huntsman, D.; Berchuck, A. Loss of arid1a-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int. J. Gynecol. Cancer 2012, 22, 9-14.
106. Yamamoto, S.; Tsuda, H.; Takano, M.; Tamai, S.; Matsubara, O. Pik3ca mutations and loss of arid1a protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch. 2012, 460, 77-87.
107. Xiao, W.; Awadallah, A.; Xin, W. Loss of arid1a/baf250a expression in ovarian endometriosis and clear cell carcinoma. Int. J. Clin. Exp. Pathol. 2012, 5, 642-650.
108. Samartzis, E.P.; Samartzis, N.; Noske, A.; Fedier, A.; Caduff, R.; Dedes, K.J.; Fink, D.; Imesch, P. Loss of arid1a/baf250a-expression in endometriosis: A biomarker for risk of carcinogenic transformation? Mod. Pathol. 2012, 25, 885-892.
109. Ayhan, A.; Mao, T.L.; Seckin, T.; Wu, C.H.; Guan, B.; Ogawa, H.; Futagami, M.; Mizukami, H.; Yokoyama, Y.; Kurman, R.J., et al. Loss of arid1a expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int. J. Gynecol. Cancer 2012, 22, 1310-1315.
110. Bosse, T.; Ter Haar, N.T.; Seeber, L.M.; Diest, P.J.; Hes, F.J.; Vasen, H.F.; Nout, R.A.; Creutzberg, C.L.; Morreau, H.; Smit, V.T. Loss of arid1a expression and its relationship with pi3k-akt pathway alterations, tp53 and microsatellite instability in endometrial cancer. Mod. Pathol. 2013, doi:10.1038/modpathol.2013.1096.
111. Han, G.; Sidhu, D.; Duggan, M.A.; Arseneau, J.; Cesari, M.; Clement, P.B.; Ewanowich, C.A.; Kalloger, S.E.; Kobel, M. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod. Pathol. 2013, doi:10.1038/modpathol.2013.1102.
112. Allo, G.; Bernardini, M.Q.; Wu, R.C.; Shih, I.M.; Kalloger, S.; Pollett, A.; Gilks, C.B.; Clarke, B.A. Arid1a loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod. Pathol. 2013, doi:10.1038/modpathol.2013.1144.
113. Engelman, J.A. Targeting pi3k signalling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9, 550-562.
114. Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8, 627-644.
115. Wullschleger, S.; Loewith, R.; Hall, M.N. Tor signaling in growth and metabolism. Cell 2006, 124, 471-484.
116. Yin, X.; Pavone, M.E.; Lu, Z.; Wei, J.; Kim, J.J. Increased activation of the pi3k/akt pathway compromises decidualization of stromal cells from endometriosis. J. Clin. Endocrinol. Metab. 2012, 97, E35-E43.
117. Honda, H.; Barrueto, F.F.; Gogusev, J.; Im, D.D.; Morin, P.J. Serial analysis of gene expression reveals differential expression between endometriosis and normal endometrium. Possible roles for axl and shc1 in the pathogenesis of endometriosis. Reprod. Biol. Endocrinol. 2008, 6, 59.
118. Zhang, H.; Zhao, X.; Liu, S.; Li, J.; Wen, Z.; Li, M. 17betae2 promotes cell proliferation in endometriosis by decreasing pten via nfkappab-dependent pathway. Mol. Cell. Endocrinol. 2010, 317, 31-43.
119. Laudanski, P.; Szamatowicz, J.; Kowalczuk, O.; Kuzmicki, M.; Grabowicz, M.; Chyczewski, L. Expression of selected tumor suppressor and oncogenes in endometrium of women with endometriosis. Hum. Reprod. 2009, 24, 1880-1890.
120. Li, M.Q.; Luo, X.Z.; Meng, Y.H.; Mei, J.; Zhu, X.Y.; Jin, L.P.; Li, D.J. Cxcl8 enhances proliferation and growth and reduces apoptosis in endometrial stromal cells in an autocrine manner via a cxcr1-triggered pten/akt signal pathway. Hum. Reprod. 2012, 27, 2107-2116.
121. Zhang, H.; Li, M.; Zheng, X.; Sun, Y.; Wen, Z.; Zhao, X. Endometriotic stromal cells lose the ability to regulate cell-survival signaling in endometrial epithelial cells in vitro. Mol. Hum. Reprod. 2009, 15, 653-663.
122. Matsuzaki, S.; Canis, M.; Vaurs-Barriere, C.; Boespflug-Tanguy, O.; Dastugue, B.; Mage, G. Dna microarray analysis of gene expression in eutopic endometrium from patients with deep endometriosis using laser capture microdissection. Fertil. Steril. 2005, 84, S1180-S1190.
123. Grund, E.M.; Kagan, D.; Tran, C.A.; Zeitvogel, A.; Starzinski-Powitz, A.; Nataraja, S.; Palmer, S.S. Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappab in human endometriotic epithelial cells. Mol. Pharmacol. 2008, 73, 1394-1404.
124. Klemmt, P.A.; Carver, J.G.; Kennedy, S.H.; Koninckx, P.R.; Mardon, H.J. Stromal cells from endometriotic lesions and endometrium from women with endometriosis have reduced decidualization capacity. Fertil. Steril. 2006, 85, 564-572.
125. Aghajanova, L.; Hamilton, A.; Kwintkiewicz, J.; Vo, K.C.; Giudice, L.C. Steroidogenic enzyme and key decidualization marker dysregulation in endometrial stromal cells from women with versus without endometriosis. Biol. Reprod. 2009, 80, 105-114.
126. Velarde, M.C.; Aghajanova, L.; Nezhat, C.R.; Giudice, L.C. Increased mitogen-activated protein kinase kinase/extracellularly regulated kinase activity in human endometrial stromal fibroblasts of women with endometriosis reduces 3',5'-cyclic adenosine 5'-monophosphate inhibition of cyclin d1. Endocrinology 2009, 150, 4701-4712.
127. Wynn, R.M. Ultrastructural development of the human decidua. Am. J. Obstet. Gynecol. 1974, 118, 652-670.
128. Feroze-Zaidi, F.; Fusi, L.; Takano, M.; Higham, J.; Salker, M.S.; Goto, T.; Edassery, S.; Klingel, K.; Boini, K.M.; Palmada, M., et al. Role and regulation of the serum- and glucocorticoid-regulated kinase 1 in fertile and infertile human endometrium. Endocrinology 2007, 148, 5020-5029.
129. Labied, S.; Kajihara, T.; Madureira, P.A.; Fusi, L.; Jones, M.C.; Higham, J.M.; Varshochi, R.; Francis, J.M.; Zoumpoulidou, G.; Essafi, A., et al. Progestins regulate the expression and activity of the forkhead transcription factor foxo1 in differentiating human endometrium. Mol. Endocrinol. 2006, 20, 35-44.
130. Kim, J.J.; Kurita, T.; Bulun, S.E. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr. Rev. 2013, 34, 130-162.
131. Banerjee, S.; Kaye, S.B. New strategies in the treatment of ovarian cancer: Current clinical perspectives and future potential. Clin. Cancer Res. 2013, 19, 961-968.
132. Kuo, K.T.; Mao, T.L.; Jones, S.; Veras, E.; Ayhan, A.; Wang, T.L.; Glas, R.; Slamon, D.; Velculescu, V.E.; Kuman, R.J., et al. Frequent activating mutations of pik3ca in ovarian clear cell carcinoma. Am. J. Pathol. 2009, 174, 1597-1601.
133. Hashiguchi, Y.; Tsuda, H.; Inoue, T.; Berkowitz, R.S.; Mok, S.C. Pten expression in clear cell adenocarcinoma of the ovary. Gynecol. Oncol. 2006, 101, 71-75.
134. Tan, D.S.; Iravani, M.; McCluggage, W.G.; Lambros, M.B.; Milanezi, F.; Mackay, A.; Gourley, C.; Geyer, F.C.; Vatcheva, R.; Millar, J., et al. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin. Cancer Res. 2011, 17, 1521-1534.
135. Carden, C.P.; Stewart, A.; Thavasu, P.; Kipps, E.; Pope, L.; Crespo, M.; Miranda, S.; Attard, G.; Garrett, M.D.; Clarke, P.A., et al. The association of pi3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol. Cancer Ther. 2012, 11, 1609-1617.
136. Tan, D.S.; Miller, R.E.; Kaye, S.B. New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br. J. Cancer 2013, 108, 1553-1559.
137. Yamamoto, S.; Tsuda, H.; Takano, M.; Iwaya, K.; Tamai, S.; Matsubara, O. Pik3ca mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J. Pathol. 2011, 225, 189-194.
138. Campbell, I.G.; Russell, S.E.; Choong, D.Y.; Montgomery, K.G.; Ciavarella, M.L.; Hooi, C.S.; Cristiano, B.E.; Pearson, R.B.; Phillips, W.A. Mutation of the pik3ca gene in ovarian and breast cancer. Cancer Res. 2004, 64, 7678-7681.
139. Wang, Y.; Helland, A.; Holm, R.; Kristensen, G.B.; Borresen-Dale, A.L. Pik3ca mutations in advanced ovarian carcinomas. Hum. Mutat. 2005, 25, 322.
140. Levine, D.A.; Bogomolniy, F.; Yee, C.J.; Lash, A.; Barakat, R.R.; Borgen, P.I.; Boyd, J. Frequent mutation of the pik3ca gene in ovarian and breast cancers. Clin. Cancer Res. 2005, 11, 2875-2878.
141. Willner, J.; Wurz, K.; Allison, K.H.; Galic, V.; Garcia, R.L.; Goff, B.A.; Swisher, E.M. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum. Pathol. 2007, 38, 607-613.
142. Rahman, M.; Nakayama, K.; Rahman, M.T.; Nakayama, N.; Ishikawa, M.; Katagiri, A.; Iida, K.; Nakayama, S.; Otsuki, Y.; Shih, I.M., et al. Clinicopathologic and biological analysis of pik3ca mutation in ovarian clear cell carcinoma. Hum. Pathol. 2012, 43, 2197-2206.
143. McConechy, M.K.; Ding, J.; Senz, J.; Yang, W.; Melnyk, N.; Tone, A.A.; Prentice, L.M.; Wiegand, K.C.; McAlpine, J.N.; Shah, S.P., et al. Ovarian and endometrial endometrioid carcinomas have distinct ctnnb1 and pten mutation profiles. Mod. Pathol. 2013, doi:10.1038/modpathol.2013.1107.
144. Vestergaard, A.L.; Thorup, K.; Knudsen, U.B.; Munk, T.; Rosbach, H.; Poulsen, J.B.; Guldberg, P.; Martensen, P.M. Oncogenic events associated with endometrial and ovarian cancers are rare in endometriosis. Mol. Hum. Reprod. 2011, 17, 758-761.
145. Janku, F.; Wheler, J.J.; Westin, S.N.; Moulder, S.L.; Naing, A.; Tsimberidou, A.M.; Fu, S.; Falchook, G.S.; Hong, D.S.; Garrido-Laguna, I., et al. Pi3k/akt/mtor inhibitors in patients with breast and gynecologic malignancies harboring pik3ca mutations. J. Clin. Oncol. 2012, 30, 777-782.
146. Church, D.; Koppensteiner, R.; Yap, T.; Fink, D.; Dedes, K. Pi3k-akt-mtor inhibitors for the systematic treatment of endometrial cancer. Expert Rev. Obstet. Gynecol. 2012, 5, 421-430.
147. Yap, T.A.; Carden, C.P.; Kaye, S.B. Beyond chemotherapy: Targeted therapies in ovarian cancer. Nat. Rev. Cancer 2009, 9, 167-181.
148. Mabuchi, S.; Kawase, C.; Altomare, D.A.; Morishige, K.; Sawada, K.; Hayashi, M.; Tsujimoto, M.; Yamoto, M.; Klein-Szanto, A.J.; Schilder, R.J., et al. Mtor is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin. Cancer Res. 2009, 15, 5404-5413.
149. Verhaak, R.G.; Tamayo, P.; Yang, J.Y.; Hubbard, D.; Zhang, H.; Creighton, C.J.; Fereday, S.; Lawrence, M.; Carter, S.L.; Mermel, C.H., et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 2013, 123, 517-525.
150. Mabuchi, S.; Altomare, D.A.; Cheung, M.; Zhang, L.; Poulikakos, P.I.; Hensley, H.H.; Schilder, R.J.; Ozols, R.F.; Testa, J.R. Rad001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin. Cancer Res. 2007, 13, 4261-4270.
151. Di Nicolantonio, F.; Arena, S.; Tabernero, J.; Grosso, S.; Molinari, F.; Macarulla, T.; Russo, M.; Cancelliere, C.; Zecchin, D.; Mazzucchelli, L., et al. Deregulation of the pi3k and kras signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest. 2010, 120, 2858-2866.
152. Ihle, N.T.; Lemos, R.; Wipf, P.; Yacoub, A.; Mitchell, C.; Siwak, D.; Mills, G.B.; Dent, P.; Kirkpatrick, D.L.; Powis, G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor px-866 whereas oncogenic ras is a dominant predictor for resistance. Cancer Res. 2009, 69, 143-150.
153. Shimizu, T.; Tolcher, A.W.; Papadopoulos, K.P.; Beeram, M.; Rasco, D.W.; Smith, L.S.; Gunn, S.; Smetzer, L.; Mays, T.A.; Kaiser, B., et al. The clinical effect of the dual-targeting strategy involving pi3k/akt/mtor and ras/mek/erk pathways in patients with advanced cancer. Clin. Cancer Res. 2012, 18, 2316-2325.
154. Gao, X.; Tate, P.; Hu, P.; Tjian, R.; Skarnes, W.C.; Wang, Z. Es cell pluripotency and germ-layer formation require the swi/snf chromatin remodeling component baf250a. Proc. Natl. Acad. Sci. USA 2008, 105, 6656-6661.
155. Luo, B.; Cheung, H.W.; Subramanian, A.; Sharifnia, T.; Okamoto, M.; Yang, X.; Hinkle, G.; Boehm, J.S.; Beroukhim, R.; Weir, B.A., et al. Highly parallel identification of essential genes in cancer cells. Proc. Natl. Acad. Sci. USA 2008, 105, 20380-20385.
156. Nagl, N.G.; Wang, X.; Patsialou, A.; van Scoy, M.; Moran, E. Distinct mammalian swi/snf chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J. 2007, 26, 752-763.
157. Nagl, N.G.; Patsialou, A.; Haines, D.S.; Dallas, P.B.; Beck, G.R.; Moran, E. The p270 (arid1a/smarcf1) subunit of mammalian swi/snf-related complexes is essential for normal cell cycle arrest. Cancer Res. 2005, 65, 9236-9244.
158. Zhang, X.; Zhang, Y.; Yang, Y.; Niu, M.; Sun, S.; Ji, H.; Ma, Y.; Yao, G.; Jiang, Y.; Shan, M., et al. Frequent low expression of chromatin remodeling gene arid1a in breast cancer and its clinical significance. Cancer Epidemiol. 2012, 36, 288-293.
159. Liang, H.; Cheung, L.W.; Li, J.; Ju, Z.; Yu, S.; Stemke-Hale, K.; Dogruluk, T.; Lu, Y.; Liu, X.; Gu, C., et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012, 22, 2120-2129.
160. Darr, J.; Klochendler, A.; Isaac, S.; Eden, A. Loss of igfbp7 expression and persistent akt activation contribute to smarcb1/snf5-mediated tumorigenesis. Oncogene 2013, doi:10.1038/onc.2013.261.
161. Guan, B.; Wang, T.L.; Shih, I.M. In Arid1a Loss in Collaboration with pi3k Pathway Activation Leads to Ovarian Tumorigenesis in Mouse, Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, USA, 6-10 April 2013; Walter, E., Ed.; AACR: Philadelphia, PA, USA, 2013; LB-259.
162. Gui, Y.; Guo, G.; Huang, Y.; Hu, X.; Tang, A.; Gao, S.; Wu, R.; Chen, C.; Li, X.; Zhou, L., et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 2011, 43, 875-878.
163. Fadare, O.; Renshaw, I.L.; Liang, S.X. Does the loss of arid1a (baf-250a) expression in endometrial clear cell carcinomas have any clinicopathologic significance? A pilot assessment. J. Cancer 2012, 3, 129-136.